Seegene Collaborates with Thermo to Enter US Market
By LabMedica International staff writers Posted on 29 May 2017 |
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Seegene develops high multiplex molecular diagnostic assays for the global market using its proprietary real-time PCR technologies. Seegene’s Allplex assay is capable of providing Ct values for multiple targets in a single tube or well and when combined with Thermo Fisher's PCR System, it will offer a comprehensive MDx solution. Seegene's portfolio of syndromic panel products, which includes various sexually transmitted infections, gastrointestinal, and respiratory pathogen detection assays, will be first introduced in the U.S. market. Thermo Fisher's dominant position in instrumentation will allow Seegene's multiplex detection technologies to establish a strong foothold in the U.S. market.
“The U.S. is the world's largest MDx market. Well versed in advanced detection technologies, it also has the strongest customer demands,” said Seegene's CEO, Dr. Jong-Yoon Chun. “The synergistic combination of Thermo Fisher's newest instrument and Seegene's powerful multiplex PCR chemistry technologies will enable us to gain U.S. market share by offering advanced detection methods to more physicians and patients.”
“We are proud to collaborate with Seegene as we move forward to seek FDA clearance for our respective platforms in parallel,” said Kim Kelderman, vice president and general manager of Genetic Analysis at Thermo Fisher Scientific. “We are committed to working with global partners who share our vision of driving better health outcomes.”
Seegene develops high multiplex molecular diagnostic assays for the global market using its proprietary real-time PCR technologies. Seegene’s Allplex assay is capable of providing Ct values for multiple targets in a single tube or well and when combined with Thermo Fisher's PCR System, it will offer a comprehensive MDx solution. Seegene's portfolio of syndromic panel products, which includes various sexually transmitted infections, gastrointestinal, and respiratory pathogen detection assays, will be first introduced in the U.S. market. Thermo Fisher's dominant position in instrumentation will allow Seegene's multiplex detection technologies to establish a strong foothold in the U.S. market.
“The U.S. is the world's largest MDx market. Well versed in advanced detection technologies, it also has the strongest customer demands,” said Seegene's CEO, Dr. Jong-Yoon Chun. “The synergistic combination of Thermo Fisher's newest instrument and Seegene's powerful multiplex PCR chemistry technologies will enable us to gain U.S. market share by offering advanced detection methods to more physicians and patients.”
“We are proud to collaborate with Seegene as we move forward to seek FDA clearance for our respective platforms in parallel,” said Kim Kelderman, vice president and general manager of Genetic Analysis at Thermo Fisher Scientific. “We are committed to working with global partners who share our vision of driving better health outcomes.”
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus